Dendreon’s Provenge Cancer Vaccine Shows “Substantial Efficacy” – Cmte.

Although not convinced that existing data fully prove the efficacy of Dendreon's Provenge, a majority of FDA's Cellular, Tissue and Gene Therapies Advisory Committee agreed during a March 29 meeting that there is "substantial evidence" the biologic is effective and should be approved